A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion.

Hanno Andreas Ohmann, Niclas Kuper, Jan Wacker
Author Information
  1. Hanno Andreas Ohmann: Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany. ORCID
  2. Niclas Kuper: Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany. ORCID
  3. Jan Wacker: Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany.

Abstract

Dopamine (DA) is known to be involved in various aspects of reward processing and goal-directed behavior. The present preregistered study aims at directly accessing the causal influence of DA activity on reward motivation in humans, while also accounting for trait extraversion. Therefore, we examined the effect of a single dose of the DA D2 receptor antagonist sulpiride (200 mg) on effort allocation in a modified version of the Effort-Expenditure for Reward Task (EEfRT). Based on its presumably DA increasing action, we expected the low dose of sulpiride to increase participants' willingness to allocate effort during the modified EEfRT relative to placebo, especially in trials with low probability of reward attainment. Further, we expected a moderating effect of trait extraversion on the effects of sulpiride. Two hundred and three healthy male participants were tested in a randomized, double-blind between-subjects design. Contrary to our expectations, sulpiride reduced the average number of clicks within the modified EEfRT and did not interact with reward attributes, suggesting a more global and not reward-specific effect of sulpiride. Furthermore, trait extraversion did not moderate the effect of sulpiride. Our results provide initial support for the validity of the modified version of the EEfRT, suggesting a possible inhibiting effect of a low dose of sulpiride on approach motivation regardless of trait extraversion. However, given the mixed pattern of findings and the possible confounding role of motoric abilities, further studies examining these effects are clearly warranted.

Keywords

References

  1. Cogn Emot. 2016;30(3):458-71 [PMID: 25759131]
  2. Pharmacopsychiatry. 1999 Jul;32(4):127-35 [PMID: 10505482]
  3. Trends Cogn Sci. 2013 Jun;17(6):281-6 [PMID: 23623264]
  4. Schizophr Bull. 2015 Sep;41(5):1055-65 [PMID: 26209546]
  5. J Neurosci. 2010 Aug 18;30(33):11096-103 [PMID: 20720117]
  6. Curr Behav Neurosci Rep. 2015 Sep;2(3):146-153 [PMID: 26525751]
  7. Behav Brain Res. 1994 Dec 15;65(2):221-9 [PMID: 7718155]
  8. Psychiatry Res. 2014 Dec 30;220(3):874-82 [PMID: 25262638]
  9. Biometrics. 1986 Mar;42(1):121-30 [PMID: 3719049]
  10. Neuropsychopharmacology. 2018 Oct;43(11):2180-2189 [PMID: 30082890]
  11. J Neurosci. 2017 Feb 15;37(7):1708-1720 [PMID: 28202786]
  12. Science. 2015 Aug 28;349(6251):aac4716 [PMID: 26315443]
  13. Psychol Sci. 2013 Apr;24(4):489-97 [PMID: 23447558]
  14. Psychophysiology. 2018 Jan;55(1): [PMID: 28459501]
  15. Eur Neuropsychopharmacol. 2019 May;29(5):629-642 [PMID: 30879927]
  16. Psychopharmacology (Berl). 2015 Apr;232(7):1313-23 [PMID: 25323625]
  17. Transl Psychiatry. 2016 Jul 05;6(7):e850 [PMID: 27378550]
  18. J Neurosci. 2015 Mar 4;35(9):4104-11 [PMID: 25740537]
  19. J Neurosci. 2011 Nov 2;31(44):15818-25 [PMID: 22049425]
  20. Psychopharmacology (Berl). 2007 Apr;191(3):483-95 [PMID: 17119929]
  21. J Pers Soc Psychol. 2002 May;82(5):804-18 [PMID: 12003479]
  22. Neuroscience. 2014 Dec 12;282:13-22 [PMID: 24463000]
  23. Neurosci Biobehav Rev. 2011 Jan;35(3):537-55 [PMID: 20603146]
  24. Neuroimage. 2005 May 1;25(4):1133-45 [PMID: 15850731]
  25. J Pharmacol Exp Ther. 1999 Feb;288(2):774-81 [PMID: 9918588]
  26. Cell. 1995 Dec 29;83(7):1197-209 [PMID: 8548806]
  27. Eur Neuropsychopharmacol. 2011 Mar;21(3):282-6 [PMID: 21112746]
  28. J Neurosci. 2017 Jun 21;37(25):6087-6097 [PMID: 28539420]
  29. J Pers Soc Psychol. 2006 Jul;91(1):171-87 [PMID: 16834487]
  30. Pharmacol Rev. 2011 Mar;63(1):182-217 [PMID: 21303898]
  31. J Neurochem. 1975 Apr;24(4):707-10 [PMID: 1123624]
  32. Schizophr Bull. 2013 May;39(3):673-83 [PMID: 22315480]
  33. Brain Res. 1983 Mar 28;264(1):105-10 [PMID: 6133578]
  34. Psychophysiology. 2018 Jan;55(1): [PMID: 28306164]
  35. Curr Top Behav Neurosci. 2016;27:231-57 [PMID: 26323245]
  36. Clin Neuropharmacol. 1990;13 Suppl 1:S76-83 [PMID: 2199037]
  37. Mol Psychiatry. 2005 Jan;10(1):79-104 [PMID: 15289815]
  38. J Neurosci. 2011 Nov 16;31(46):16597-602 [PMID: 22090487]
  39. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2649-65 [PMID: 24035741]
  40. Front Neural Circuits. 2013 Oct 11;7:152 [PMID: 24130517]
  41. Schizophr Bull. 2015 Sep;41(5):1045-54 [PMID: 26142081]
  42. PLoS One. 2015 Jun 26;10(6):e0131357 [PMID: 26115223]
  43. eNeuro. 2018 Apr 6;5(2): [PMID: 29632870]
  44. Am J Psychiatry. 2009 Jun;166(6):702-10 [PMID: 19411368]
  45. Psychopharmacology (Berl). 2008 Aug;199(3):457-80 [PMID: 18311558]
  46. Schizophr Res. 2016 Feb;170(2-3):278-84 [PMID: 26763628]
  47. Cortex. 2015 Aug;69:40-6 [PMID: 25967086]
  48. PLoS One. 2009 Aug 12;4(8):e6598 [PMID: 19672310]
  49. Soc Cogn Affect Neurosci. 2015 Jul;10(7):1015-9 [PMID: 25479792]
  50. Neuropsychology. 2016 Sep;30(6):685-96 [PMID: 27054437]
  51. Drug Saf. 1996 May;14(5):288-98 [PMID: 8800626]
  52. Neuropsychopharmacology. 2014 Sep;39(10):2366-75 [PMID: 24713613]
  53. Neural Netw. 2006 Oct;19(8):1302-14 [PMID: 16949252]
  54. Front Hum Neurosci. 2013 Apr 08;7:117 [PMID: 23580360]
  55. J Neurosci. 2003 Nov 26;23(34):10827-31 [PMID: 14645475]
  56. Front Behav Neurosci. 2018 Mar 23;12:52 [PMID: 29628879]
  57. Behav Brain Sci. 1999 Jun;22(3):491-517; discussion 518-69 [PMID: 11301519]
  58. Int J Neuropsychopharmacol. 2014 Dec;17(12):2045-56 [PMID: 24964269]
  59. Brain. 2018 May 1;141(5):1455-1469 [PMID: 29672668]
  60. Personal Neurosci. 2019 Jul 26;2:e3 [PMID: 32435738]
  61. Curr Dir Psychol Sci. 2013 Jun 1;22(3):244-249 [PMID: 24748727]
  62. Cereb Cortex. 2009 Oct;19(10):2240-7 [PMID: 19131436]
  63. Am J Epidemiol. 1986 Oct;124(4):678-83 [PMID: 3752061]
  64. Physiol Rev. 1998 Jan;78(1):189-225 [PMID: 9457173]
  65. Annu Rev Clin Psychol. 2017 May 8;13:471-495 [PMID: 28301764]
  66. Behav Brain Res. 2015 Mar 15;281:283-9 [PMID: 25546724]
  67. Biol Psychol. 2007 Jan;74(1):46-59 [PMID: 16904812]
  68. Neurosci Biobehav Rev. 2016 Jun;65:21-35 [PMID: 26959336]
  69. Neuropsychologia. 2018 Oct;119:417-423 [PMID: 30193845]
  70. J Abnorm Psychol. 2012 Aug;121(3):553-8 [PMID: 22775583]
  71. Cell Tissue Res. 2004 Oct;318(1):93-106 [PMID: 15503151]
  72. Cogn Affect Behav Neurosci. 2014 Jun;14(2):756-68 [PMID: 24323704]
  73. J Abnorm Psychol. 2014 May;123(2):387-97 [PMID: 24886012]

Word Cloud

Created with Highcharts 10.0.0sulpirideextraversionrewardtraiteffectEEfRTDAmodifiedlowmotivationdoseeffortDopamineantagonistallocationversionexpectedeffectssuggestingpossibleregardlessknowninvolvedvariousaspectsprocessinggoal-directedbehaviorpresentpreregisteredstudyaimsdirectlyaccessingcausalinfluenceactivityhumansalsoaccountingThereforeexaminedsingleD2receptor200mgEffort-ExpenditureRewardTaskBasedpresumablyincreasingactionincreaseparticipants'willingnessallocaterelativeplaceboespeciallytrialsprobabilityattainmentmoderatingTwohundredthreehealthymaleparticipantstestedrandomizeddouble-blindbetween-subjectsdesignContraryexpectationsreducedaveragenumberclickswithininteractattributesglobalreward-specificFurthermoremoderateresultsprovideinitialsupportvalidityinhibitingapproachHowevergivenmixedpatternfindingsconfoundingrolemotoricabilitiesstudiesexaminingclearlywarranteddosagedopamineD2-receptoraffectsApproachSulpirideTrait

Similar Articles

Cited By